TapewireFind a company

person · Reporting owner

SMITH IAN F

Disclosed activity across 7 companies

Tapewire entity
16070
SEC CIK
0001197032

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Acorda Therapeutics, Inc.ACOR · Entity 111987DirectorJune 27, 2018June 29, 2018
Foghorn Therapeutics Inc.FHTX · Entity 5820DirectorJune 24, 2026June 25, 2026
INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802DirectorJune 12, 2018June 14, 2018
Odyssey Therapeutics, Inc.ODTX · Entity 4850DirectorMay 07, 2026May 12, 2026
Solid Biosciences Inc.SLDB · Entity 4915DirectorOctober 02, 2026October 06, 2026
Stoke Therapeutics, Inc.STOK · Entity 1723Director · Chief Executive OfficerFebruary 17, 2026February 19, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875EVP, COOJune 29, 2018July 03, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Acorda Therapeutics, Inc.

Report date June 27, 2018 · Filed June 29, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.15 · Expires 2028-06-27Direct15,000 Reported balance After 2018-06-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-06-27 · Grant · Acquired 15,000 · Balance 15,000

F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.

Foghorn Therapeutics Inc.

Report date June 24, 2026 · Filed June 25, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23Direct28,000 Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000

F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

INFINITY PHARMACEUTICALS, INC.

Report date June 12, 2018 · Filed June 14, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect45,845 Reported balance After 2018-06-12 transaction · row 1
1 source row

Row 1 · 2018-06-12 · Grant · Acquired 22,857 · Balance 45,845

F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12Direct20,000 Reported balance After 2018-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000

F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12Direct4,000 Reported balance After 2018-06-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2018-06-12 · Grant · Acquired 4,000 · Balance 4,000

F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.

F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.

Odyssey Therapeutics, Inc.

Report date May 07, 2026 · Filed May 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06Direct27,393 Reported balance After 2026-05-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393

F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

Solid Biosciences Inc.

Report date October 02, 2026 · Filed October 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect141,585 Reported balance After 2026-10-02 transaction · row 1
1 source row

Row 1 · 2026-10-02 · Exercise / conversion · Acquired 3,440 · Balance 141,585

F1: Restricted stock units convert to common stock on a one-for-one basis.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect3,440 Reported balance After 2026-10-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-10-02 · Exercise / conversion · Disposed 3,440 · Balance 3,440

F1: Restricted stock units convert to common stock on a one-for-one basis.

F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units convert to common stock on a one-for-one basis.

F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Stoke Therapeutics, Inc.

Report date February 17, 2026 · Filed February 19, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.09 · Expires 2036-02-16Direct193,000 Reported balance After 2026-02-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-17 · Grant · Acquired 193,000 · Balance 193,000

F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2030-02-15Direct129,000 Reported balance After 2026-02-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-02-17 · Grant · Acquired 129,000 · Balance 129,000

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

VERTEX PHARMACEUTICALS INC / MA

Report date June 29, 2018 · Filed July 03, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect46,699 Ending reported balance After 2018-06-29 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2018-06-29 · Exercise / conversion · Acquired 23,375 · Balance 70,074

Row 2 · 2018-06-29 · Sale · Disposed 4,741 · Balance 65,333

F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Row 3 · 2018-06-29 · Sale · Disposed 18,634 · Balance 46,699

F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.89 · Expires 2025-07-20Direct10,625 Reported balance After 2018-06-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-06-29 · Exercise / conversion · Disposed 23,375 · Balance 10,625

F5: The option vests in 16 quarterly installments from 7/21/2015.

Common StockSEC Table I · non-derivativeIndirect401(k)5,306 Reported balance Holding disclosure · report date 2018-06-29 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 5,306

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).

F5: The option vests in 16 quarterly installments from 7/21/2015.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 02, 2026 Filed Oct 6, 2026 20:35 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 3,440 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-415649 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,440

Underlying: Common Stock · 3,440 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

F2 · derivative.expiration_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Read SEC document
October 02, 2026 Filed Oct 6, 2026 20:35 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 3,440 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-415649 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
July 02, 2026 Filed Jul 7, 2026 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 3,440 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-297456 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,880

Underlying: Common Stock · 3,440 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

F2 · derivative.expiration_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Read SEC document
July 02, 2026 Filed Jul 7, 2026 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 3,440 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-297456 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
June 24, 2026 Filed Jun 25, 2026 20:02 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Options (Right to buy) · Derivative 28,000 $4.08 Strike: $4.08 $114,240.00
Disclosure

SEC source: 0001197032-26-000005 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Read SEC document
June 10, 2026 Filed Jun 11, 2026 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 77,500 $0.00 Strike: $6.61 $0.00
Disclosure

SEC source: 0001193125-26-267503 · ownership.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2036-06-10

F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
May 07, 2026 Filed May 12, 2026 00:30 UTC Odyssey Therapeutics, Inc. ODTX · Entity 4850 GrantStock Option (Right to Buy) · Derivative 27,393 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001193125-26-217592 · ownership.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,393

Underlying: Common Stock · 27,393 shares

Expires 2036-05-06

F1 · derivative.exercise_date: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
April 02, 2026 Filed Apr 2, 2026 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 3,441 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-140056 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,320

Underlying: Common Stock · 3,441 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

F2 · derivative.expiration_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Read SEC document
April 02, 2026 Filed Apr 2, 2026 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 3,441 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-140056 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,705

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:24 UTC Stoke Therapeutics, Inc. STOK · Entity 1723 GrantRestricted Stock Units · Derivative 129,000 $0.00 $0.00
Disclosure

SEC source: 0001197032-26-000002 · form4-02192026_090250.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,000

Underlying: Common Stock · 129,000 shares

Expires 2030-02-15

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:24 UTC Stoke Therapeutics, Inc. STOK · Entity 1723 GrantEmployee Stock Option (Right to Buy) · Derivative 193,000 $0.00 Strike: $31.09 $0.00
Disclosure

SEC source: 0001197032-26-000002 · form4-02192026_090250.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,000

Underlying: Common Stock · 193,000 shares

Expires 2036-02-16

F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

Read SEC document
January 06, 2026 Filed Jan 7, 2026 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 4,573 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-006287 · ownership.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

F4 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Read SEC document
January 06, 2026 Filed Jan 7, 2026 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 4,573 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-006287 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
January 02, 2026 Filed Jan 7, 2026 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 13,761 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-006287 · ownership.xml · derivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,761

Underlying: Common Stock · 13,761 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").

F2 · derivative.exercise_date: The Smith RSUs (as defined in footnote 3) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 2, 2026 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Fourth Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

F2 · derivative.expiration_date: The Smith RSUs (as defined in footnote 3) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 2, 2026 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Fourth Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
January 02, 2026 Filed Jan 7, 2026 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantStock Option (Right to Buy) · Derivative 18,012 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0001193125-26-006287 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,012

Underlying: Common Stock · 18,012 shares

Expires 2036-01-02

F2 · derivative.exercise_date: The Smith RSUs (as defined in footnote 3) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 2, 2026 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Fourth Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
October 08, 2025 Filed Oct 14, 2025 20:16 UTC Stoke Therapeutics, Inc. STOK · Entity 1723 GrantRestricted Stock Units · Derivative 380,000 $0.00 $0.00
Disclosure

SEC source: 0001197032-25-000004 · form4-10142025_081006.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 380,000

Underlying: Common Stock · 380,000 shares

Expires 2029-10-06

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F3 · derivative.exercise_date: The award shall vest as to 1/4 of the total award annually on the sixth calendar day of October, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 6, 2026.

Read SEC document
October 08, 2025 Filed Oct 14, 2025 20:16 UTC Stoke Therapeutics, Inc. STOK · Entity 1723 GrantStock Option (Right to Buy) · Derivative 570,000 $0.00 Strike: $30.50 $0.00
Disclosure

SEC source: 0001197032-25-000004 · form4-10142025_081006.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 570,000

Underlying: Common Stock · 570,000 shares

Expires 2035-10-07

F1 · derivative.exercise_date: The option shall vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 of the total award vesting monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.

Read SEC document
October 06, 2025 Filed Oct 7, 2025 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 4,573 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-233445 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,573

Underlying: Common Stock · 4,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
October 06, 2025 Filed Oct 7, 2025 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 4,573 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-233445 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
July 06, 2025 Filed Jul 9, 2025 00:04 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 4,573 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-094690 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,146

Underlying: Common Stock · 4,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
July 06, 2025 Filed Jul 9, 2025 00:04 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 4,573 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-094690 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
June 17, 2025 Filed Jun 17, 2025 20:29 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Option (right to buy) · Derivative 25,000 $4.79 Strike: $4.79 $119,750.00
Disclosure

SEC source: 0001562180-25-004909 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-06-16

Read SEC document
June 12, 2025 Filed Jun 13, 2025 20:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 77,500 $0.00 Strike: $4.58 $0.00
Disclosure

SEC source: 0000950170-25-086248 · ownership.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2035-06-12

F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
April 06, 2025 Filed Apr 8, 2025 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 4,574 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-052050 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,719

Underlying: Common Stock · 4,574 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
April 06, 2025 Filed Apr 8, 2025 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 4,574 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-052050 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
March 20, 2025 Filed Mar 20, 2025 22:19 UTC Stoke Therapeutics, Inc. STOK · Entity 1723 GrantStock Option (Right to Buy) · Derivative 238,420 $0.00 Strike: $8.33 $0.00
Disclosure

SEC source: 0001415889-25-008715 · form4-03202025_100340.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,420

Underlying: Common Stock · 238,420 shares

Expires 2035-03-19

F1 · derivative.exercise_date: The option vests ratably as to 1/12 of the total award on the monthly anniversary of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date.

Read SEC document
January 06, 2025 Filed Jan 7, 2025 22:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 18,293 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-003052 · ownership.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,293

Underlying: Common Stock · 18,293 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").

F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

F3 · derivative.expiration_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
January 06, 2025 Filed Jan 7, 2025 22:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantStock Option (Right to Buy) · Derivative 22,148 $0.00 Strike: $4.10 $0.00
Disclosure

SEC source: 0000950170-25-003052 · ownership.xml · derivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,148

Underlying: Common Stock · 22,148 shares

Expires 2035-01-06

F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 22:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 3,255 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-003052 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,255 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 22:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 3,255 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-003052 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,972

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
October 03, 2024 Filed Oct 4, 2024 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 3,255 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-112898 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,255

Underlying: Common Stock · 3,255 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
October 03, 2024 Filed Oct 4, 2024 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 3,255 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-112898 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 03, 2024 Filed Jul 5, 2024 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 3,255 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-081866 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,510

Underlying: Common Stock · 3,255 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
July 03, 2024 Filed Jul 5, 2024 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 3,255 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-081866 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,462

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 20:06 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Options (Right to buy) · Derivative 16,000 $5.52 Strike: $5.52 $88,320.00
Disclosure

SEC source: 0001562180-24-005361 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-25

Read SEC document
June 11, 2024 Filed Jun 13, 2024 20:11 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 34,400 $0.00 Strike: $7.51 $0.00
Disclosure

SEC source: 0000950170-24-073006 · ownership.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,400

Underlying: Common Stock · 34,400 shares

Expires 2034-06-11

F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:23 UTC Stoke Therapeutics, Inc. STOK · Entity 1723 GrantDirector Stock Option (Right to Buy) · Derivative 7,639 $0.00 Strike: $16.41 $0.00
Disclosure

SEC source: 0001415889-24-015970 · form4-06072024_080629.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,639

Underlying: Common Stock · 7,639 shares

Expires 2034-06-04

F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

Read SEC document
April 03, 2024 Filed Apr 5, 2024 20:45 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 3,256 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-042322 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,765

Underlying: Common Stock · 3,256 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
April 03, 2024 Filed Apr 5, 2024 20:45 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 3,256 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-042322 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,207

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 03, 2024 Filed Jan 6, 2024 00:02 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 13,021 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-002598 · ownership.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,021

Underlying: Common Stock · 13,021 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").

F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

F3 · derivative.expiration_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
January 03, 2024 Filed Jan 6, 2024 00:02 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantStock Option (Right to Buy) · Derivative 15,112 $0.00 Strike: $5.76 $0.00
Disclosure

SEC source: 0000950170-24-002598 · ownership.xml · derivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,112

Underlying: Common Stock · 15,112 shares

Expires 2034-01-03

F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
January 03, 2024 Filed Jan 6, 2024 00:02 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 15,570 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-002598 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,570 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
January 03, 2024 Filed Jan 6, 2024 00:02 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 15,570 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-002598 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,948

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

Read SEC document
December 08, 2023 Filed Dec 12, 2023 21:00 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Option (right to buy) · Derivative 26,977 $0.00 Strike: $5.63 $0.00
Disclosure

SEC source: 0001562180-23-008311 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,977

Underlying: Common Stock · 26,977 shares

Expires 2033-12-07

F1 · derivative.exercise_date: The option was granted pursuant to a consulting agreement effective December 8, 2023 (the "Effective Date"). The option will vest as to 1/12 of the underlying shares of common stock on the first day of each month beginning on January 1, 2024, with the balance of then-unvested shares to vest one year after the Effective Date.

Read SEC document
October 03, 2023 Filed Oct 5, 2023 19:13 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 15,569 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-052171 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,570

Underlying: Common Stock · 15,569 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted units convert to common on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the First Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the First Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
October 03, 2023 Filed Oct 5, 2023 19:13 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 15,569 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-23-052171 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,378

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted units convert to common on a one-for-one basis.

Read SEC document
September 19, 2023 Filed Sep 20, 2023 20:48 UTC Stoke Therapeutics, Inc. STOK · Entity 1723 GrantDirector Stock Option (Right to Buy) · Derivative 96,340 $0.00 Strike: $4.76 $0.00
Disclosure

SEC source: 0001209191-23-050170 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,340

Underlying: Common Stock · 96,340 shares

Expires 2033-09-18

F1 · derivative.exercise_date: The option vests ratably as to 1/12th of the total award on December 19, 2023, with 1/12th of the total award vesting quarterly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 17:40 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 15,570 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-031954 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,139

Underlying: Common Stock · 15,570 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 17:40 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 15,570 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-23-031954 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted units convert into common stock on a one-for-one basis.

Read SEC document
June 21, 2023 Filed Jun 23, 2023 00:13 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Option (right to buy) · Derivative 16,000 $0.00 Strike: $8.70 $0.00
Disclosure

SEC source: 0001562180-23-005478 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-06-20

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.